Evaluating the Effectiveness and Safety of Colon Capsule Endoscope System for Capturing and Viewing Colon Images

Prospective Study Clinical Trial

Official title:

A Prospective, Multi-center, Randomized and Self-controlled Clinical Trial to Evaluate the Effectiveness and Safety of Colon Capsule Endoscope System for Capturing and Viewing Colon Images Clinically

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05308511
• Other study ID #: AK-CTP-01
• Status: Completed
• Phase: N/A
• Start date: April 1, 2022
• Est. completion date: August 4, 2023

Study information

• Verified date: April 2022
• Source: Wuhan Union Hospital, China
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The trial is a prospective,multi-center, randomized and self-controlled clinical trial. The research plan will be implemented in a clinical trial center with the qualification of clinical trial agency, and 128 subjects will be planned to be included. Subjects signing the Informed Consent Form, meeting the trial conditions and all inclusion criteria and failing to meet any exclusion criteria will be included in the research. The trial device was Colon Capsule Endoscope System for colonoscopy(PC-I) manufactured by ANKON Technologies Co.,Ltd. while the comparator device was Capsule Endoscopy System(PillCam COLON2) manufactured by Given Imaging Inc. The main evaluation indicator is the excellent rate of image quality, while secondary evaluation indicators are the consistency rate of lesion detection, completion rate of colonoscopy, discharge time of capsule endoscopy, colon passing time and device performance evaluation. Safety evaluation indicators include adverse events(or Serious adverse events), device-related adverse events(or Serious adverse events) and device defects. In the end, the effectiveness and safety of Colon Capsule Endoscopy diagnostic system manufactured by ANKON Technologies Co.,Ltd. for capturing and viewing colon images clinically were verified according to the above indicator results.

Description:

According to the relevant requirements of Standard for Quality Management of Medical Device Clinical Trials (Order No. 25 of the National Health and Family Planning Commission of the People's Republic of China of China Food and Drug Administration), the sample size was estimated based on the excellent rate of the image quality of the main endpoint by referring to the domestic and foreign literatures using positive comparator devices. Combined with literatures and comments of clinical experts, the research set the excellent rate of image quality of comparator device Ps as 95%, and estimated the excellent rate of image quality of trial device Pt as 95%. In the research, the non-inferiority trial design was adopted, with α = 0.025 (unilateral), assurance 1 - β = 0.8, and non-inferiority boundary value of -10%, and self-control was adopted. It is assumed that the redundant parameter (that is, the proportion of subjects whose evaluation results of image quality between trial devices and comparator devices are inconsistent) was 0.095 (that is, Pt (1 - Ps) + Ps (1 - Pt)), the total sample size of the two groups was 102 cases calculated by PASS2021, with 51 cases in each swallowing orders I and II. Considering the shedding and rejection rate of 20% during the trial, a total of 128 subjects were needed, with 64 cases in each swallowing orders I and II.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 128
• Est. completion date: August 4, 2023
• Est. primary completion date: May 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years old (including 18 years old), male or female;
• Subjects intending to take capsule endoscopy and/or the electronic endoscopy of the lower digestive tract;
• The subject signed the ICF voluntarily.

Exclusion Criteria:

• Subjects suffering from swallowing obstruction or deglutition disorders;
• Subjects who underwent gastrointestinal abdominal surgery in the past 6 month (except for simple surgery unlikely to cause intestinal obstruction according to the clinical judgment of researchers).
• Subjects of CRC (advanced adenomatous polyp and CRC) failing to undergo the surgery;
• Subjects suffering from gastrointestinal obstruction, stenosis or fistula;
• Subjects being unable to take capsule endoscopy due to intestinal preparation failure;
• Subjects with cardiac pacemakers or other implantable electronic medical devices;
• Subjects failing to meet requirements for the abdominal surgery or refusing to take any abdominal surgery;
• Female subjects during pregnancy, lactation or having a pregnancy plan recent 3 months;
• Subjects who underwent colonoscopy within 2 years, with the negative result;
• Subjects suffering from type 1 or type 2 diabetes;
• Subject taking incomplete colonoscopy due to enteropathy of severe ulcerative colitis, radiation enteritis or non-steroidal anti-inflammatory drugs[4];
• Subjects suffering from any disease considered to increase the retention risk of the capsule endoscopy;
• Subjects currently participating in another clinical trial of drugs or devices;
• Other circumstances unsuitable for inclusion upon judgment by the researcher.

Related Conditions & MeSH terms

• Prospective Study

Intervention

Device:
• PC-I and COLON2
First swallow the trial device(PC-I) for examination, and then swallow the comparator device(COLON2) for examination at an interval of 2h.
• COLON2 and PC-I
First swallow the comparator device(COLON2) for examination, and then swallow the trial device(PC-I) for examination at an interval of 2h.

Locations

Country	Name	City	State
China	Union Hospital of Tongji Medical College of Huazhong University of Science and Technology	Wuhan	Hubei

Sponsors (3)

Lead Sponsor	Collaborator
Wuhan Union Hospital, China	Beijing Tsinghua Changgeng Hospital, Renmin Hospital of Wuhan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The excellent rate of image quality.	The main effectiveness evaluation indicator is the excellent rate of image quality, which is for the statistics of the difference between the excellent rate of image quality of trial devices and comparator devices and unilateral 97.5% confidence interval. If the lower limit of unilateral 97.5% confidence interval of the difference between the two groups is greater than -10% of the non-inferiority boundary value, it can be considered that the excellent rate of image quality of trial devices is not inferior to that of comparator devices.	1 day
Secondary	The consistency rate of lesion detection	2 associate chief physicians of digestive endoscopy or attending physicians with more than 5 years of endoscopic experience adopted independent film reading in the center for recording of the lesion detection in the image through back-to-back interpretation and analysis. Then record the number of lesions detected consistently.	1 day
Secondary	Completion rate of colonoscopy	Colonoscopy is completed before the battery runs out, and the capsule endoscopy captures the rectal segment image or the image that the capsule endoscopy is discharged from the body.	1-14 days
Secondary	Discharge time of capsule endoscopy	The discharge time of the capsule endoscopy is from swallowing capsule endoscopy to discharging capsule endoscopy.	1-14 days
Secondary	Colon passing time	Colon passing time is from the capsule endoscopy's arrival at the ileocecal valve to the capsule endoscopy's discharge from the body.	0.5-10hours
Secondary	Device performance evaluation	Subjective evaluation of the performance of the trial and control devices.	1day